Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder

Journal of Immunology Research
Heiner ZimmermannS Oertel


We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy. Previous reports had indicated that the lower affinity F allele affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and is linked to inferior outcome of rituximab monotherapy in B cell malignancies. 25 patients with PTLD after solid organ transplantation were included in this analysis. They had received 4 weekly doses of rituximab as part of two clinical trials, which had a rituximab monotherapy induction regimen in common. 16/25 patients received further treatment with CHOP-21 after rituximab monotherapy (PTLD-1, NCT01458548). The FCGR3A status was correlated to the response after 4 cycles of rituximab monotherapy. Response to rituximab monotherapy was not affected by F carrier status. This is in contrast to previous findings in B cell malignancies where investigators found a predictive impact of FCGR3A status on outcome to rituximab monotherapy. One explanation for this finding could be that ADCC is impaired in transplant recipients receiving immunosuppression. These results suggest that carrying a FCRG3A F allele does not negatively affect rituximab therapy ...Continue Reading


Oct 1, 1981·Clinical Immunology and Immunopathology·R J ten BergeJ M Wilmink
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Jun 12, 2003·Journal of Immunological Methods·Sébastien Dall'OzzoGilles Thibault
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Nov 24, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S H K OertelH B Riess
Nov 21, 2007·Haematologica·Eva González-BarcaUNKNOWN GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas)
Jan 16, 2008·Transplant Infectious Disease : an Official Journal of the Transplantation Society·H Clauss, R Samuel
Feb 20, 2008·Transplant International : Official Journal of the European Society for Organ Transplantation·Maria Boratyńska, Danuta Smolska
Jul 31, 2010·Journal of Leukocyte Biology·Tae-Jin KimKyung-Mi Lee
Oct 5, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D N EissensI Joosten
Jan 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Guillaume CartronMichael Hallek
Oct 26, 2011·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Jamie P NourseMaher K Gandhi

❮ Previous
Next ❯

Methods Mentioned


Clinical Trials Mentioned


Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.